Tesamorelin Reconstitution Calculator

Yes. Tesamorelin is FDA-approved as a subcutaneous growth hormone-releasing hormone (GHRH) analog for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, not as a general weight-loss drug or sports-performance peptide (RCT/regulatory-context). The strongest clinical evidence is in people with HIV and central fat accumulation, where it reduces visceral adipose tissue (VAT) by about 10–15% over 26 weeks in phase 3 trials (RCT).

Tesamorelin selectively targets visceral fat more than total body weight. In HIV-associated lipodystrophy, it reduces VAT, waist circumference, trunk fat, and hepatic fat, while increasing lean body mass and generally not lowering BMI much, so it is better thought of as a body-composition drug than a scale-weight drug (RCT). It also increases IGF-1 as part of its mechanism and may improve fat “quality” on CT density measures, not just quantity (RCT).

The studied standard is 2 mg subcutaneously once daily, typically into abdominal skin (RCT). In trials, clinically meaningful VAT reduction was seen by 26 weeks, and 12-month treatment maintained or extended benefit, whereas fat tended to reaccumulate after stopping (RCT). Community protocol: many users rotate abdominal injection sites daily and dose at a consistent time of day.

Yes in practice. The evidence base and approved use are for subcutaneous injection; oral use is not established because tesamorelin is a peptide and peptide oral bioavailability is generally poor (RCT/mechanistic). If the goal is evidence-based use, subcutaneous is the only route supported by human outcome data (RCT).

Human trials support 6 months as the usual initial efficacy window and up to 12 months with ongoing benefit in HIV-associated visceral adiposity (RCT). Longer use may be reasonable when benefit persists and IGF-1 and glucose remain acceptable, but long-term outcome data beyond the core trial periods are limited (RCT/observational extension). Community protocol: reassess at 3–6 months using waist circumference, fasting glucose/HbA1c, and, if available, imaging or body-composition data.

Usually not dramatically, but it can. In HIV trials and a randomized trial in type 2 diabetes, tesamorelin increased IGF-1 and was generally metabolically tolerable, but hyperglycemia can occur and glucose monitoring is important (RCT). Practical implication: people with prediabetes, diabetes, or rapid weight gain on ART should track fasting glucose and HbA1c during therapy (RCT).

Common adverse effects include injection-site reactions, arthralgia, myalgia, peripheral edema/fluid retention symptoms, and paresthesias; carpal tunnel-type symptoms are also a recognized concern in pharmacovigilance and GH-axis therapy generally (RCT/pharmacovigilance). Serious toxicity was not a dominant signal in the main trials, but tolerability depends on IGF-1 rise, fluid retention sensitivity, and glycemic response (RCT).

Pregnancy: avoid; tesamorelin is contraindicated because reducing visceral fat in pregnancy has no therapeutic role and fetal safety is not the target setting (practitioner consensus; regulatory framing reflected in reviews). Active malignancy: avoid or use only with specialist input, because GH/IGF-1 axis stimulation is a concern and product labeling/reviews emphasize this contraindication (review/regulatory-context). General fat loss without HIV lipodystrophy: evidence is weak; GLP-1 receptor agonists have much stronger obesity data, whereas tesamorelin is targeted to HIV-associated excess visceral fat (RCT/review).

Tesamorelin is more selective for visceral fat redistribution in HIV lipodystrophy, while GLP-1 receptor agonists cause broader total-body weight loss and also reduce visceral and liver fat (RCT/review). If someone has normal or mildly elevated BMI with disproportionate central/visceral fat, tesamorelin fits the phenotype better; if someone has generalized obesity, GLP-1 therapy usually has stronger total-weight evidence (case-based/review). Some clinicians consider sequential or combined strategies in complex HIV fat-distribution phenotypes, but that is evolving practice, not established standard (case report/review).

Practical handling follows the product formulation and pharmacy instructions; injectable peptide formulations commonly require temperature control before use, so confirm the exact storage rules on your dispensed label (practitioner consensus). For travel, keep it in original packaging, carry injection supplies in hand luggage, and bring the prescription or medication letter (practitioner consensus). If antidoping matters, note that GHRH analogs including tesamorelin are prohibited in sport and are specifically detectable in anti-doping testing (analytical/antidoping).